Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Implementation of Biomimetic 3D Bioprinting Technology in Selecting Optimal Regimens as Adjuvant Therapy to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection or Ablation: a Feasibility Study

NCT07839767 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT07839767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07839767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Implementation of Biomimetic 3D Bioprinting Technology in Selecting Optimal Regimens as Adjuvant Therapy to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection or Ablation: a Feasibility Study
Lead sponsor
The University of Hong Kong
Phase
Observational
Overall status
Recruiting
Start date
April 13, 2026
Completion date
December 31, 2031
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma